Zacks Research Has Pessimistic Outlook of Neogen Q1 Earnings

Neogen Corporation (NASDAQ:NEOG - Free Report) - Stock analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Neogen in a research note issued on Wednesday, July 2nd. Zacks Research analyst R. Department now anticipates that the company will earn $0.08 per share for the quarter, down from their previous forecast of $0.09. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q1 2027 earnings at $0.10 EPS.

NEOG has been the topic of several other research reports. Guggenheim cut their price objective on shares of Neogen from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday. Piper Sandler dropped their target price on shares of Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd.

Neogen Stock Up 1.8%

NEOG traded up $0.10 during trading on Friday, hitting $5.33. The stock had a trading volume of 4,019,215 shares, compared to its average volume of 3,509,253. The company has a market capitalization of $1.16 billion, a PE ratio of -2.39 and a beta of 1.77. Neogen has a twelve month low of $3.87 and a twelve month high of $18.58. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.45 and a current ratio of 3.91. The stock has a 50 day simple moving average of $5.59 and a two-hundred day simple moving average of $8.33.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its quarterly earnings data on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The business had revenue of $221.00 million during the quarter, compared to the consensus estimate of $225.27 million. Neogen had a positive return on equity of 2.69% and a negative net margin of 53.56%. The business's quarterly revenue was down 3.4% on a year-over-year basis. During the same period last year, the firm earned $0.12 EPS.

Institutional Investors Weigh In On Neogen

A number of large investors have recently bought and sold shares of the company. Harbour Investments Inc. acquired a new stake in Neogen during the 4th quarter valued at approximately $27,000. Versant Capital Management Inc raised its holdings in shares of Neogen by 1,495.4% during the first quarter. Versant Capital Management Inc now owns 3,127 shares of the company's stock worth $27,000 after purchasing an additional 2,931 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in Neogen during the fourth quarter valued at $43,000. Covestor Ltd lifted its position in Neogen by 41.4% during the fourth quarter. Covestor Ltd now owns 4,103 shares of the company's stock valued at $50,000 after purchasing an additional 1,202 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Neogen by 388.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 10,071 shares of the company's stock valued at $87,000 after purchasing an additional 8,010 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company's stock.

Insider Transactions at Neogen

In other news, Director James P. Tobin acquired 10,000 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were acquired at an average cost of $4.73 per share, with a total value of $47,300.00. Following the completion of the acquisition, the director owned 37,474 shares of the company's stock, valued at approximately $177,252.02. This trade represents a 36.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Aashima Gupta bought 16,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $6.25 per share, with a total value of $100,000.00. Following the acquisition, the director directly owned 21,917 shares of the company's stock, valued at approximately $136,981.25. This trade represents a 270.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 83,500 shares of company stock worth $431,525 over the last 90 days. Insiders own 1.13% of the company's stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.